NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
Clinical Trials
86 trialsNCT06483555 2026-04-01
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT04683315 2026-03-05
PANCREAS
Medical College of Wisconsin
Phase 2 Recruiting
NCT02021422 2026-02-18
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Baylor Research Institute
Phase 1 Completed
NCT04340141 2026-02-10
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT07214298 2026-02-06
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT06381154 2026-01-30
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Recruiting
NCT03977233 2026-01-13
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT03322995 2026-01-08
PANC
Medical College of Wisconsin
Phase 2 Recruiting
NCT03443492 2025-12-30
Pancreas
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT05391126 2025-12-16
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
University of Kentucky
Phase NA Recruiting
NCT04753879 2025-12-04
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06941857 2025-12-03
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT04821284 2025-11-04
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Thomas Jefferson University
Phase 1/2 Active not recruiting
NCT04141995 2025-08-07
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
Phase 2 Terminated
NCT04594772 2025-07-02
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT06897644 2025-05-25
PANThEON
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT03750669 2025-05-13
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Completed
NCT02896907 2025-04-30
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03822936 2025-02-13
PIOPPO
CNAO National Center of Oncological Hadrontherapy
Phase 2 Terminated
NCT03699319 2025-01-23
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01821612 2025-01-13
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase EARLY_PHASE1 Completed
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01905150 2024-12-11
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Bruckner Oncology
Phase 2 Completed
NCT02919787 2024-11-20
Nordic Pancreatic Cancer Trial (NorPACT) - 1
Oslo University Hospital
Phase 2/3 Active not recruiting
NCT04927780 2024-08-28
PREOPANC-3
Erasmus Medical Center
Phase 3 Recruiting
NCT04672005 2024-05-16
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT04447092 2024-04-19
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
Phase 2 Active not recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT02539537 2024-01-09
NEOPAN
UNICANCER
Phase 3 Completed
NCT06166589 2023-12-12
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT04324307 2023-09-01
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Changhai Hospital
Phase 1/2 Unknown
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT01835041 2023-07-12
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT02333188 2023-05-31
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
Phase 1 Completed
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT02028806 2023-02-16
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Completed
NCT01926197 2022-10-28
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Stanford University
Phase 3 Completed
NCT03099265 2022-10-27
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Yale University
Phase 2 Terminated
NCT00025168 2021-09-09
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT02368860 2021-06-01
OXIRI
National Cancer Centre, Singapore
Phase 1 Completed
NCT01591733 2021-05-28
FOLFIRINOX + RT for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT00112658 2021-03-08
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
UNICANCER
Phase 2/3 Completed
NCT01397019 2020-11-02
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Odense University Hospital
Phase 2 Completed
NCT02172976 2020-09-02
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
Krankenhaus Nordwest
Phase 2/3 Completed